Shots:
- Bio Usawa Biotechnology and Bioeq AG entered into an agreement to make ranibizumab biosimilar for serious retinal diseases, accessible to millions in Sub-Saharan Africa
- The partnership gives Bio Usawa exclusive rights to register and market Bioeq’s ranibizumab biosimilar, BioUcenta, advancing access to essential biologics in Sub-Saharan Africa
- BioUcenta, an intravitreal injection, blocks abnormal retinal blood vessel growth and fluid leakage—major causes of vision loss. Approved in Europe and the US, it will now be registered and distributed in Sub-Saharan Africa by Bio Usawa
Ref: GlobeNewsWire | Image: Bio Usawa Biotechnology and Bioeq AG | Press Release
Related News:- Fresenius kabi Secures the CHMP’s Positive Opinion for Bomyntra & Conexxence (Biosimilar, Prolia and Xgeva)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
